Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
9 hedge funds and large institutions have $315K invested in Rosetta Genomics Ltd. in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
18% less funds holding
Funds holding: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
54% less capital invested
Capital invested by funds: $689K → $315K (-$374K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$132K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$33K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$630 |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$307 |
| 5 |
Citigroup
New York
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$248K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
-$21K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $183K | +$132K | +24,439 | +65% |
|
|
HCM
2
Highlander Capital Management
Short Hills,
New Jersey
| $97K | -$2.88K | -534 | -2% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $34K | +$33K | +6,127 | +116% |
|
4
SEI Investments
Oaks,
Pennsylvania
| $1K | -$5 | -1 | -0.4% |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| – | -$248K | -49,278 | Closed |
|
|
6
California Public Employees Retirement System
Sacramento,
California
| – | -$21K | -4,217 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$18K | -3,545 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$9K | -1,698 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$3.23K | -600 | -83% |
|
|
10
Citigroup
New York
| – | +$5 | +1 | +1% |
|
|
AG
11
Advisor Group
Phoenix,
Arizona
| – | +$307 | +57 | New |
|
|
12
Creative Planning
Overland Park,
Kansas
| – | +$630 | +117 | New |
|
ROSG Hedge Fund Activity: Q1 2017 in Review
9 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q1 2017, worth a combined $315K — down 54% from $689K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ROSG and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $132K. The largest seller was Sabby Management, exiting entirely with an estimated $248K sold.
- 9 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q1 2017, down from 11 in Q4 2016.
- Funds reported $315K of Rosetta Genomics Ltd. stock for Q1 2017, down 54% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q1 2017 and 4 closed out, a net change of -2 holders.
- The largest Rosetta Genomics Ltd. buyer in Q1 2017 was Morgan Stanley, an estimated $132K added.
- The largest Rosetta Genomics Ltd. seller in Q1 2017 was Sabby Management, an estimated $248K sold.
Based on aggregated 13F filings for Q1 2017.